The Movetis story
Movetis NV was founded in Belgium in November 2006 as a spin-off of Johnson & Johnson. As a European specialty GI company, it was focused on discovering, developing and commercializing innovative treatments targeting GI conditions with a high unmet medical need. Movetis had a brief and dynamic history: in October 2009 it acquired the authorization in 30 European countries to market Resolor (prucalopride) for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. This was followed by a successful IPO on NYSE Euronext in December 2009 and the commercial launch of Resolor in the first European markets in the first half of 2010. In November 2010 the company was acquired by Shire and integrated into the Shire structure under the name Shire-Movetis. At the end of 2012 Shire decided to close the Shire-Movetis organization, which closure became effective during the second quarter of 2013.
Movetis, Shire-Movetis and Shire are trademarks of the Shire group of companies.
© Copyright 2013 - Progress Pharma NV | Disclaimer | Design by BlueCie